Company profileAdjacent technology
NGoggle
Goggles that test the visual field by reading the brain's response, without asking the patient to press a button.
- Location
- San Diego, United States
- Class
- Adjacent technologyIt reads EEG to measure vision, as a diagnostic. Nothing is decoded for the wearer to control or say, so it is listed as adjacent and not counted as a BCI company.Not counted among core BCI companies.
- Sources last checked
- 6 Oct 2026
What they are building
The nGoggle is a portable, wireless head-mounted unit that records the brain's steady-state response to visual stimulation across the field of view, as an objective test for damage from glaucoma.
- Interface category
- Electroencephalography
- Signal
- Summed field potentials, blurred and attenuated by skull and scalp
- Invasiveness
- Non-invasive
- Recording / stimulation
- Recording
- Main use cases
- Monitor
Where they are clinically
Feasibility
Small early studies that test safety and whether the device can do what it is meant to.
Its one registered study began in February 2019. The record has not been updated since February 2020 and the registry lists its status as unknown. The registry names the sponsor without an address; the city shown is from search results we did not open.
Access today
Experimental human research
Demonstrated in a small number of research participants. Not an established treatment.
- Shown in people
- In a peer-reviewed study of 33 people with glaucoma and 17 with healthy eyes, the device's measure separated the two groups with an area under the curve of 0.92, against 0.81 for standard perimetry (JAMA Ophthalmology, 2017).
- Still an aim
- An objective visual-field test for use in the clinic.
- What stands in the way
- A record that ends in 2020: the registered study has not reported.
On record here: 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this company matters
The nGoggle uses BCI methods for a measurement, not for control. Standard visual-field testing depends on the patient noticing and responding; reading the visual cortex removes that dependence. It shows the same signals serving diagnosis. The public record stops in 2020, so we cannot say whether the company is still active.
Key milestones
11 Feb 2019
A study of visual-function assessment with the device begins at Duke University Eye Center; 200 participants planned.
1 Jun 2017
Paper reports that the device distinguishes glaucomatous from healthy eyes: area under the curve 0.92, in 33 participants with glaucoma and 17 without.
Competitive context
Sources
- 01
Peer reviewedJAMA Ophthalmology1 Jun 2017Checked against source 6 Oct 2026
DOI 10.1001/jamaophthalmol.2017.0738. Figures read from the PubMed abstract.
- 02
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor NGoggle. 200 participants planned at Duke University Eye Center; started 11 February 2019; last updated 27 February 2020; the registry lists the status as unknown.
- 03
Portable brain-computer device for detecting glaucoma (opens in a new tab)
Independent reportingAmerican Academy of Ophthalmology, EyeNet1 Jul 2017Checked against source 6 Oct 2026
Describes the device as a portable, wireless head-mounted unit that records multifocal steady-state visual-evoked potentials, and reports the 2017 paper. It names no company.